Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.30.

Several research firms have recently weighed in on VNDA. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Truist Financial began coverage on Vanda Pharmaceuticals in a report on Thursday, March 5th. They set a “buy” rating and a $18.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Monday, April 20th. HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday. Finally, Zacks Research cut Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in VNDA. Torren Management LLC bought a new stake in Vanda Pharmaceuticals in the fourth quarter valued at approximately $25,000. Russell Investments Group Ltd. boosted its holdings in Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares during the last quarter. Quarry LP bought a new stake in Vanda Pharmaceuticals in the third quarter valued at approximately $53,000. Cerity Partners LLC bought a new stake in Vanda Pharmaceuticals in the second quarter valued at approximately $69,000. Finally, Boothbay Fund Management LLC bought a new stake in Vanda Pharmaceuticals in the third quarter valued at approximately $72,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $6.03 on Friday. The stock has a market cap of $362.58 million, a P/E ratio of -1.49 and a beta of 0.62. The company has a current ratio of 2.16, a quick ratio of 2.15 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average is $6.72 and its 200-day moving average is $6.99. Vanda Pharmaceuticals has a 1-year low of $4.14 and a 1-year high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.13). The firm had revenue of $51.72 million for the quarter, compared to the consensus estimate of $54.98 million. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%. Equities research analysts anticipate that Vanda Pharmaceuticals will post -2.27 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.